A Cystic Fibrosis Foundation Therapeutics funded study, maternal and fetal outcomes in the era of CFTR modulators (MAYFLOWERS) will prospectively evaluate the impact of the use of this class of drugs on the health of women with CF and their infants. Here, CFTR is linked to cystic fibrosis.